



СРПСКИ АРХИВ
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО
SERBIAN ARCHIVES
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia

+381 11 4092 776, Fax: +381 11 3348 653

E-mail: office@srpskiarhiv.rs, Web address: www.srpskiarhiv.rs

Paper Accepted*

ISSN Online 2406-0895

Case Report / Приказ болесника

Dragana Ratković*, Vladimir Knežević, Aleksandra Dickov, Maša Čomić, Predrag Savić

Abuse and addictive potential of pregabalin

Злоупотреба и адиктивни потенцијал прегабалина

University of Novi Sad, Faculty of Medicine Novi Sad, Serbia;

Clinical Center of Vojvodina, Psychiatry Clinic, Novi Sad, Serbia

Received: September 21, 2022

Revised: June 30, 2023

Accepted: July 7, 2023

Online First: July 11, 2023

DOI: <https://doi.org/10.2298/SARH220921070R>

***Accepted papers** are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. *Srp Arh Celok Lek*. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

***Correspondence to:**

Dragana RATKOVIĆ

Hajduk Veljkova 3, University of Novi Sad, Faculty of Medicine, 21000 Novi Sad, Serbia

E-mail: dragana.ratkovic@mf.uns.ac.rs

Abuse and addictive potential of pregabalin

Злоупотреба и адиктивни потенцијал прегабалина

SUMMARY

Introduction In the Republic of Serbia, pregabalin was marketed for the first time in 2006. Although the abuse of pregabalin has not been a common topic in the literature so far, it is often seen in everyday practice. Also, it seems that it is more common among addicts.

Case outline Mr. D. is a 41-year-old male patient, a perennial polytoxicomaniac on buprenorphine substitution therapy. He began using pregabalin because it caused euphoria and elevated mood, in daily doses which varies between 1050–2100 mg. The highest daily dose was 4200 mg. At the time he was admitted to the hospital for pregabalin detoxification, he met the general criteria for addiction syndrome. On admission, the patient was tense, anxious, irritable, drenched in sweat, and had insomnia. With an adequate dose of buprenorphine, the patient continued to complain about the reduction of the pregabalin dose and insisted on adjusting the dose. Shortly he was discharged from hospital at his personal request. After a month, during the check-up examination, he was diagnosed with a relapse of pregabalin use. He was readmitted to the hospital for detoxification treatment, the pregabalin dose was gradually reduced by 100 mg per week. After that the patient went to therapeutic community to continue treatment.

Conclusion This case indicates that practitioners have to be cautious when prescribing pregabalin to people prone to addiction. Further research is needed to identify risk factors for the development of pregabalin abuse syndrome, as well as to create clear guidelines for the treatment of abstinence syndrome.

Keywords: pregabalin; addiction; abuse; abstinence syndrome

САЖЕТАК

Увод На територији Републике Србије прегабалин је први пут стављен у промет 2006. године. Иако до сада злоупотреба прегабалина није била честа тема у литератури, лекари је често могу видети у свакодневној пракси. Такође, чини се да је она чешће заступљена међу особама које су зависници.

Приказ болесника Господин Д. је 41-годишњи пацијент мушког пола, вишегодишњи политоксикоман на супституционој терапији бупренорфином. Прегабалин почиње да злоупотребљава због ефекта еуфорије и повишеног расположења и то у просечној дневној дози 1050–2100 mg. Највиша дневна доза коју је пацијент конзумирао била је 4200 mg. У моменту када је примљен у болницу ради детоксикације испуњавао је опште критеријуме за синдром зависности. При пријему напет, узнемирен, раздражљив, анксиозан, орошен знојем, са несаницом. По ординирању адекватне дозе бупренорфина, пацијент је и даље износио жалбе везане за редукцију дозе прегабалина, те инсистирао на корекцији исте. Отпуштен на лични захтев. На контролном прегледу након месец дана дијагностикован је рецидив злоупотребе прегабалина. Поново је примљен у болницу ради детоксикационог третмана. Прегабалин је дисконтинуиран постепено смањивањем дозе за 100mg недељно, те је упућен у терапијску заједницу где је наставио лечење.

Закључак Овај случај указује на мере опреза коју лекари треба да имају приликом прописивања прегабалина особама склоним развоју зависности. Потребна су даља истраживања ради идентификовања фактора ризика за развој злоупотребе прегабалина, као и јасне смернице за третман апстиненцијалног синдрома.

Кључне речи: прегабалин; зависност; злоупотреба; апстиненцијални синдром

INTRODUCTION

Pregabalin is an analog of gamma-amino butyric acid, and its effect is achieved by binding to an auxiliary subunit ($\alpha 2\text{-}\delta$ protein) of voltage-dependent calcium channels in the central nervous system [1]. There are several therapeutic indications for the use of pregabalin. In Serbia, it is used in the treatment of neuropathic pain, and epilepsy, as well as for treating generalized anxiety disorder [2]. Depending on the indication, the daily dose of pregabalin ranges from 150 to 600mg. In the Republic of Serbia, it was first marketed in 2006. Although so far abuse and dependence on pregabalin have not been common topics in the available

literature, it can be said that doctors often encounter these cases in practice. This has been noted both in Serbia and other countries [3, 4, 5]. Also, it seems that it is more common among addicts [6]. A study conducted in Serbia processed the results of toxicological and chemical analyses of blood and urine in postmortem cases in 2019, which recorded the potential risks of pregabalin abuse that can lead to addiction and severe poisoning with a fatal outcome [7]. For this reason, in some countries, a special warning has been added to the prescription of the drug, to increase caution when prescribing pregabalin to persons with a history of substance abuse [8]. The case report stresses out the importance of special caution when prescribing pregabalin.

This study was approved by the local ethics committee according to the Declaration of Helsinki.

CASE REPORT

Mr. D. is a 41-year-old male patient who has been treated several times because of mental disorder due to psychoactive substances at the Clinic of Psychiatry, Clinical Center of Vojvodina in Novi Sad. He is unemployed construction technician, divorced and has three children. Family history of mental disorders as well as his history of somatic illnesses is negative. As a perennial polytoxicomaniac, he started abusing diazepam and tramadol in his seventh grade of elementary school. After his parents divorced when he was in high school, he started consuming other substances such as tetrahydrocannabinol (THC), cocaine, stimulants, and finally heroin, which he used intranasally. At the age of 28, he went to the therapeutic community for detoxification treatment, where he stayed for a year. After leaving the therapeutic community, and after a short period of abstinence, he started using psychoactive substances again. In 2017, he consumed mostly opiates (buprenorphine 16-24mg per day), which he procured illegally. In September 2018, he went to an outpatient psychiatrist when, in addition to the diagnosis of opiate addiction, he was diagnosed with generalized anxiety disorder and a mild depressive episode. Diagnoses were established according to the criteria of the International Classification of Diseases 10 Version (ICD-10) (F11.2, F41.1, F32.0) and antidepressants and pregabalin were introduced into the therapy [9]. In November of the same year, he was hospitalized for the first time at the Psychiatric Clinic to receive buprenorphine substitution therapy. Therapy on the hospital discharge list included: Buprenorphine 10mg, escitalopram 20mg, pregabalin 150mg, mirtazapine 15mg. After leaving the hospital, he was non-compliant when it comes to therapy and check-in examinations. The fact that he was unstable in the buprenorphine program, he was admitted to the hospital for the second time in

December 2019. During the second hospitalization, buprenorphine therapy was reintroduced. Therapy on the hospital discharge list included: buprenorphine 16mg, escitalopram 20mg and, mirtazapine 15mg. Shortly after leaving the hospital, following the recommendation of a friend, he started abusing pregabalin in the initial dose of 1575mg. Side-effects after the initial dose manifested in the form of imbalance, dizziness, headache, and inarticulate movements. Because of this, he reduced the dose of pregabalin to 1050mg and sporadically took the stated dose with buprenorphine therapy on his own hand. The mentioned side effects did not occur during the next use. Pregabalin initially caused euphoria and elevated mood, and he described that the effects are similar to amphetamine (e.g. increased wakefulness, increased muscle strength). With pregabalin, he got the impression of an improved effect of buprenorphine therapy. Also, after the euphoria, it was easier for the patient to fall asleep and sleep peacefully for several hours. Occasional use of pregabalin gradually intensified and became more frequent, until the moment when the patient started using pregabalin every day for one year. Pregabalin was consumed orally, in the morning and the evening. Depending on the financial resources, the daily doses ranged from 1050mg to 2100mg. The highest daily dose consumed by the patient was 4200mg divided into two doses (one in the morning and one in the evening). After a year, he comes to see a psychiatrist wishing to start a pregabalin detoxification therapy. By that time, the patient had largely lost control of his pregabalin intake. On several occasions, he tried unsuccessfully to reduce the dose and stop using pregabalin. At that time the patient already met the general criteria for addiction syndrome according to the ICD -10 and showcased a strong desire to take the substance, had low self-control, demonstrated evidence of tolerance and physiological abstinence syndrome, and continued using the substance despite clear facts about undeniable harmful consequences [9]. Due to the impossibility of establishing abstinence in external conditions, the patient was hospitalized at the Psychiatric Clinic for the third time. Before the hospitalization, the patient took pregabalin at a daily dose of 2100mg. Buprenorphine was taken for the last time on the day before admission. Upon admission, the patient was tense, anxious, irritable, suffering from insomnia and excessive sweating. According to the prescription, the maximum recommended daily dose of pregabalin is 600mg – which was prescribed, as well as valproate (750mg), anxiolytic (diazepam 40mg), and hypnotic therapy (midazolam 15mg) to alleviate the symptoms of withdrawal syndrome. The laboratory analysis of the sampled blood showed that there were no significant deviations from the reference values. Discontinuation of pregabalin therapy has been initiated. The patient was stable on the adequate dose of buprenorphine. However, the patient complained about the reduction of the pregabalin dose and still insisted on the raising of the pregabalin dose. In those

moments, abstinence symptoms in the form of anxiety, irritability, tremor, and psychomotor restlessness were observed. There was a partial reduction of withdrawal symptoms during the 11 days of hospitalization with the contribution of the following therapy: diazepam 40mg, pregabalin 300mg, midazolam 15mg, sertraline 100mg, and valproate 1500mg. On the eleventh day of hospitalization, the patient insisted on being discharged from the hospital. As there were no indications for hospitalization against his will, he was discharged. After a month, he appeared at the scheduled check-up. He was in good general condition, and stable on buprenorphine substitution therapy. However, he demonstrated low self-control and a strong craving for taking pregabalin and continued taking it despite the clear facts about the undeniable harmful consequences. One week before the control examination, he started abusing pregabalin again at a dose of 1200mg per day. Excluding buprenorphine, the urine test tested negative for the presence of other psychoactive substances. The fourth hospitalization was initiated during which pregabalin (dose reduced by 100mg per week) was discontinued. The patient was hospitalized for 45 days, during which the symptoms of abstinence syndrome were reduced, the day-night rhythm was established, and symptoms and signs of anxiety were reduced, with full insight and motivation for maintaining abstinence. The process of detoxification passed without major complications. The patient struggled with maintaining abstinence in the external environment which is why he continued his treatment in the therapeutic community, where, he spent next 4 months. He is going to regular check-ups to this day.

DISCUSSION

In the case of our patient, the observed symptoms and signs of withdrawal syndrome are similar to those caused by the benzodiazepines (BZD) and opiates. However, it is interesting to note that while being stable on buprenorphine substitution (i.e. using the drug in a prescribed manner), the patient did not feel the urge and abuse other substances, but still resorted to pregabalin. Even though the pregabalin is most often used for the treatment of epilepsy and neuropathic pain, it is increasingly prescribed for the treatment of generalized anxiety disorder. One gets the impression that neither the doctors who prescribe this medicine nor the patients - are fully aware of the risk of addiction that pregabalin carries. In Serbia and many other countries around the world, there are no official guidelines for the treatment of pregabalin addiction and abstinence syndrome caused by pregabalin cessation. The National Health Service in the UK has issued a detailed instruction, i.e. a scheme for reducing the dose of

pregabalin when treating non-cancerous pain in primary health care [10]. Therefore, we were using benzodiazepines and mood stabilizers in treating symptoms of the abstinence syndrome. As identified in other similar case reports, our patient also had medical history related to a behavioral disorder caused by substance use (THC, BZD, opiates) [8, 11, 12, 13]. According to the prescription, it is not recommended to combine BZD and pregabalin therapy. For this reason, we should bear in mind the importance of accurately informing patients about the potential risk of addiction when prescribing pregabalin, especially in the case of addicts. Although there are studies that indicate the risk of abuse and addiction, mental and behavioral disorders due to the use of pregabalin did not yet get the public attention they deserve [14, 15, 16]. Regarding the mechanism of pregabalin abuse at the biological level, research results are still heterogeneous and inconsistent but in the majority of cases they are in favor of pregabalin modulatory effects on the GABA and glutamate systems. One of the studies conducted on mice, investigating potential glutamatergic mechanisms, explored the involvement of glutamate in pregabalin-seeking behavior by using ceftriaxone (CEF), a potent glutamate transporter-1 up regulator. Mice that received doses of 60 and 90mg/kg of pregabalin demonstrated drug-seeking-like behavior, which was effectively suppressed when they were pretreated with CEF [17]. The findings indicate that CEF effectively modulated the pregabalin-induced conditioned place preference (CPP), highlighting its potential as a promising candidate for developing treatments aimed at addressing pregabalin abuse. In line with this, another study states that pregabalin has the ability to influence the GABA and glutamate systems, which suggests the possibility of its potential for misuse, as well as an explanation for the development of withdrawal syndrome [18]. As we mentioned before and due to the fact that pregabalin's effect is achieved by binding to an $\alpha 2-\delta$ protein of voltage-gate calcium channels (VGCC), studies have shown that pregabalin and similar substances effectively inhibit the release of synaptic transmitters, particularly glutamate and norepinephrine, which are responsible for excitatory signals. They also induce a moderate increase in extracellular GABA levels in the brain, in a dose-dependent manner, resulting in mild GABA-mimetic effects such as relaxation and euphoria. These effects are commonly experienced at the start of drug therapy and after the use of higher-than-recommended doses [15]. Also, the authors of another study aimed to investigate the potential role of dopamine receptor-1 in the development of pregabalin-induced CPP [19]. Mice were assigned randomly to receive either saline or the dopamine-1 receptor antagonist SKF-83566. Among the group treated with pregabalin, a significant increase in the duration spent in the chamber associated with the drug was observed compared to the time spent in the chamber associated with the vehicle. Importantly, the administration of SKF-

83566, which blocks dopamine-1 receptors, completely abolished the place preference induced by pregabalin, indicating the involvement of the dopaminergic system in pregabalin-induced reward-related behavior.

The case report stresses out the importance of special caution when prescribing pregabalin. It indicates precautionary measures to keep in mind when prescribing pregabalin to persons prone to substance abuse or dependence. It is clear that these individuals stood out as a vulnerable group, but further research is needed to identify risk factors for the development of pregabalin abuse and dependence. As in our case, the most probable reason for the abuse of pregabalin lies in its euphoric effects. The effects of pregabalin when administered correctly are not questioned. Lastly, clear guidelines are needed for the treatment of abuse and abstinence syndrome in pregabalin addiction, which seems to have pandemic potential according to our experience.

Conflict of interest: None declared.

REFERENCES

1. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press; 2021 Jul 29.
2. Prescribing information Lyrica. Medicines and Medical Devices Agency of Serbia. Lyrica®. 2022 April [cited 2022 Apr 20]. Available from: <https://www.alims.gov.rs/english/medicinal-products/search-for-human-medicines/?id=440031>
3. Antunovic M, Vucinic S, Kotur-Stevuljevic J, Krstic K, Jovic-Stosic J, Kilibarda V, et al. Rise of pregabalin poisoning and abuse cases in Serbia: a ten-year retrospective study. *Int. J. Gen. Med.* 2023;1239-50. DOI: 10.2147/IJGM.S405616
4. Aneja J, Singh J. Pregabalin Use/Misuse: A Source of Consternation in Western Punjab. *Indian J. Psychol. Med.* 2023 Mar;45(2):206-7. DOI: 10.1177/02537176221081780
5. Lasheen D, Sherif N, El-Taftazani E, Atalla S, Abdellkader S. Study of Acute Pregabalin Intoxication in Patients Admitted to Poison Control Center Ain Shams University Hospitals and its Pathological Effect on Rat Brain: Clinical and Experimental Study. *AJFM.* 2023 Jan 1;40(1):85-98. DOI: 10.21608/ajfm.2023.285281
6. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. *Eur. J. Clin. Pharmacol.* 2013;69(12):2021-5. PMID: 23989299 DOI: 10.1007/s00228-013-1578-5
7. Vujović M, Kostic E, Pancic D, Milosavljević B, Stojanović I, Karadžić R, et al. Pregabalin determination in postmortem samples and toxicological significance in forensic cases. *Acta med. Median.* 2021;60(3):05-10. doi:10.5633/amm.2021.0301
8. Yazdi K, Hemetsberger U, Baier C. Pregabalin abuse of benzodiazepine and alcohol addicted patient. *Psychiatr. Danub.* 2015;27(3):0-279. PMID: 26400136
9. 10th revision of the international classification of diseases, chapter V (F): Mental and behavioral disorders (including disorders of psychological development). Genève, Switzerland: World Health Organization; 1990.
10. Southend and Castle Point & Rochford CCGs Medicines Management Team. Pregabalin and Gabapentin: Withdrawal Summary Guidance for NON-CANCER pain in adults in primary care. 2022 April [cited 2022 Apr 24]. Available from: <https://southendccg.nhs.uk/your-health-services/healthcare-professionals/medicines-management/bnf-chapter-4-nervous-system/cns-pain/3421-gabapentinoids-withdrawal-summary-guidance-v1-0-march-2020/file>
11. Gahr M, Franke B, Freudenmann RW, Kölle MA, Schönfeldt-Lecuona C. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. *J. Addict. Med.* 2013;7(2):147-9. PMID: 23519046 DOI: 10.1097/ADM.0b013e3182872718
12. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, et al. Pregabalin abuse, dependence, and withdrawal: a case report. *Am. J Psychiatry.* 2010;167(7):869. PMID: 20595436 DOI: 10.1176/appi.ajp.2010.09091269
13. Yargic I, Ozdemiroglu FA. Pregabalin abuse: a case report. *Klinik Psikofarmakol Bülteni.* 2011;21(1):64-6.
14. Brennan R, Van Hout MC. "Bursting the Lyrica bubble": experiences of pregabalin use in individuals accessing opioid substitution treatment in Dublin. *Heroin Addict. Relat. Clin. Probl.* 2020;22(6):5-13.
15. Hägg S, Jönsson AK, Ahlner J. Current evidence on abuse and misuse of gabapentinoids. *Drug Saf.* 2020;43(12):1235-54. PMID: 32857333 DOI: 10.1007/s40264-020-00985-6
16. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern?. *CNS drugs.* 2014;28(6):491-6. PMID: 24760436 DOI: 10.1007/s40263-014-0164-4
17. Althobaiti YS, Almalki A, Alsaab H, Alsanie W, Gaber A, Alhadidi Q, et al. Pregabalin: potential for addiction and a possible glutamatergic mechanism. *Sci. Rep.* 2019 Oct 22;9(1):1-8. DOI: 10.1038/s41598-019-51556-4
18. Evoy KE, Peckham AM, Covvey JR, Tidgewell KJ. Gabapentinoid pharmacology in the context of emerging misuse liability. *J. Clin. Pharmacol.* 2021 Aug;61:S89-99. DOI: 10.1002/jcph.1833
19. Althobaiti YS, Almutairi FM, Alshehri FS, Altowairqi E, Marghalani AM, Alghorabi AA, Alsanie WF, Gaber A, Alsaab HO, Almalki AH, Hakami AY. Involvement of the dopaminergic system in the reward-related behavior of pregabalin. *Sci. Rep.* 2021 May 19;11(1):10577. DOI: 10.1038/s41598-021-88429-8